Patents by Inventor Roman Krawetz

Roman Krawetz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of PRG4 as an anti-inflammatory agent
    Patent number: 11717557
    Abstract: Disclosed herein are methods of using PRG4 glycoprotein, also known as lubricin, to reduce, inhibit, or down-regulate pro-inflammatory pathways in patients at risk of or suffering from an inflammatory response or allergy symptom through CD44 antagonization, regulating pro-inflammatory cytokine production, inhibiting NF-?B translocation and/or facilitating removal of inflammation-inducing cellular or matrix debris or allergens.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: August 8, 2023
    Assignees: Lubris LLC, Rhode Island Hospital
    Inventors: Gregory D. Jay, Benjamin D. Sullivan, Tannin Avery Schmidt, Khaled Elsaid, Edward R. Truitt, Roman Krawetz, Jawed Fareed, Joanna Szmydynger-Chodobska, Adam Chodobski
  • Use of PRG4 as an Anti-Inflammatory Agent
    Publication number: 20210299214
    Abstract: Disclosed herein are methods of using PRG4 glycoprotein, also known as lubricin, to reduce, inhibit, or down-regulate pro-inflammatory pathways in patients at risk of or suffering from an inflammatory response or allergy symptom through CD44 antagonization, regulating pro-inflammatory cytokine production, inhibiting NF-?B translocation and/or facilitating removal of inflammation-inducing cellular or matrix debris or allergens.
    Type: Application
    Filed: March 8, 2021
    Publication date: September 30, 2021
    Inventors: Gregory D. Jay, Benjamin D. Sullivan, Tannin Avery Schmidt, Khaled Elsaid, Edward R. Truitt, Roman Krawetz, Jawed Fareed
  • LUBRICIN FOR USE IN WOUND HEALING
    Publication number: 20210260167
    Abstract: The application relates to uses of the proteoglycan 4 protein, also known as lubricin, in wound healing and tissue regeneration, reducing scar formation, and promoting angiogenesis.
    Type: Application
    Filed: June 21, 2019
    Publication date: August 26, 2021
    Inventors: Roman Krawetz, Saleem Abubacker, Jeffrey Alan Biernaskie, Tannin Avery Schmidt
  • Use of PRG4 as an anti-inflammatory agent
    Patent number: 10967048
    Abstract: Disclosed herein are methods of using PRG4 glycoprotein, also known as lubricin, to reduce, inhibit, or down-regulate pro-inflammatory pathways in patients at risk of or suffering from an inflammatory response or allergy symptom through CD44 antagonization, regulating pro-inflammatory cytokine production, inhibiting NF-?B translocation and/or facilitating removal of inflammation-inducing cellular or matrix debris or allergens.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: April 6, 2021
    Assignee: Lubris LLC
    Inventors: Gregory D. Jay, Benjamin D. Sullivan, Tannin Avery Schmidt, Khaled Elsaid, Edward R. Truitt, Roman Krawetz, Jawed Fareed
  • Use of PRG4 as an Anti-Inflammatory Agent
    Publication number: 20180015141
    Abstract: Disclosed herein are methods of using PRG4 glycoprotein, also known as lubricin, to reduce, inhibit, or down-regulate pro-inflammatory pathways in patients at risk of or suffering from an inflammatory response or allergy symptom through CD44 antagonization, regulating pro-inflammatory cytokine production, inhibiting NF-?B translocation and/or facilitating removal of inflammation-inducing cellular or matrix debris or allergens.
    Type: Application
    Filed: January 26, 2016
    Publication date: January 18, 2018
    Applicant: Rhode Island Hospital, A Lifespan Partner
    Inventors: Gregory D. Jay, Benjamin D. Sullivan, Tannin Avery Schmidt, Khaled Elsaid, Edward R. Truitt, Roman Krawetz, Joanna Szmydynger-Chodobska, Adam Chodobska, Jawed Fareed
  • Expansion of Embryonic Stem Cells
    Publication number: 20110263016
    Abstract: The present invention addresses the problem of expanding human embryonic stem cell (hESC) and induced pluripotent stem cell (iPSC) populations to clinically relevant numbers while maintaining pluripotency. In particular, the use of macrolide antibiotics and inhibitors of Rho and Rho-associated kinases is described.
    Type: Application
    Filed: September 25, 2009
    Publication date: October 27, 2011
    Inventors: Derrick E. Rancourt, Guoliang Meng, Shiying Lui, Xiangyun Li, Roman Krawetz, Jaymi Cormier